# 1 (Poly)phenols in Human Breast Milk and their health

# 2 benefits for the newborn

- 3 Diogo Carregosa<sup>1</sup>, Inês P. Silva<sup>1</sup>, Carolina Teixeira<sup>1</sup>, Mariana Baltazar<sup>1</sup>, Rocio García-Villalba<sup>2</sup>, Filipa
- 4 Soares Vieira<sup>3</sup>, Mónica Marçal<sup>1,3</sup>, Madalena Tuna<sup>3,4</sup>, Cláudia N. Santos<sup>1</sup>
- 5 <sup>1</sup> iNOVA4Health, NOVA Medical School | Faculdade de Ciências Médicas, Universidade NOVA de
- 6 Lisboa, Campo dos Mártires da Pátria, 1169-056 Lisboa, Portugal.
- 7 <sup>2</sup> Laboratory of Food & Health, Research Group on Quality, Safety, and Bioactivity of Plant Foods,
- 8 CEBAS-CSIC, Murcia, Spain.
- 9 <sup>3</sup> Hospital de São Francisco Xavier Centro Hospitalar de Lisboa ocidental E.P.E.
- 10 <sup>4</sup> CHRC, NOVA Medical School | Faculdade de Ciências Médicas, Universidade NOVA de Lisboa,
- 11 Campo dos Mártires da Pátria, 1169-056 Lisboa, Portugal.
- 12
- 13 Corresponding author: <u>claudia.nunes.santos@nms.unl.pt</u>
- 14
- Abbreviations used: BM, breast milk; BSID, Bayley Scales of Infant Development; DOPAC, 2-(3,4dihydroxyphenyl)acetic acid; EHC, enterohepatic circulation; FRAP, ferric reducing antioxidant power; LMW, low molecular weight; MDI, Mental Developmental Index; OAT, organic acid transporter; ORAC, oxygen radical absorbance capacity; PDI, Psychomotor Development Index; PLS-3, Preschool Language Scale-3; SC, systemic circulation; SPE, solid phase extraction; TEAC, trolox equivalent antioxidant capacity; TRAP, total reactive antioxidant potential
- 21
- 22
- 23
- 24

### 25 Abstract

26 Human breast milk is the first food source available to newborns and is responsible for 27 healthy growth and development during the first months of life. Human breast milk contains 28 vitamins, hormones, cytokines, microbiota, and immune cells that are responsible for such 29 healthy conditions. Nonetheless, knowledge of the vast array of molecules present in human 30 breast milk and their potential health effects is still lacking. The effects of mothers' diets on 31 the molecules present in human breast milk are also generally unknown. The health benefits 32 of (poly)phenols have been largely increasing but their presence in breast milk has been put 33 largely aside. The impact of the mother's diet in the presence and quantification of these 34 molecules in milk has also been overlooked. Above all, the potential benefits of 35 (poly)phenols for newborns are just a vast emptiness of what is known about (poly)phenol 36 research.

37 Keywords: Polyphenols, Breast Milk, Newborn, Metabolites, Concentrations

38

# 39 1. Introduction

40 Human breast milk is produced by the mammary gland and is essential for the healthy growth and development of newborns. Human breast milk is characterized by a huge 41 42 complexity and diversity of components, including nutrients, such as proteins, 43 carbohydrates, and lipids (1); bioactive components, such as immunoglobulins, stem cells, 44 cytokines, hormones, growth factors, and phytochemicals (2); and a vast array of bacteria, 45 such as Staphylococcus, Streptococcus, Bifidobacterium, Lactobacillus, and Clostridium 46 cluster XIVa-XIVb (3). This chemical and biological diversity of agents in its composition 47 provides the infant with well-balanced nutrition and protection against potential infectious 48 pathogens as the infant immune system develops (4). For these reasons and for optimal 49 health and growth, the World Health Organization (5) recommends that infants be 50 exclusively breastfed for the first six months of life, and that breastfeeding continues to be an

important part of the diet until the infant is at least two years old. In addition to nutrients, vitamins, cells, and other compounds beneficial for health, it is not surprising that breast milk also contains some undesirable molecules, for example xenobiotics. Environmental xenobiotics in air, water and soil are absorbed by organisms through ingestion, inhalation or dermal absorption and enter the human food chain and often can be found in milk samples (6).

57 Human breast milk is a dynamic fluid that arises from the lactation process and develops to 58 the different newborn needs. Breast milk can be classified into different stages based on its 59 chemical composition. The first stage is pre-colostrum. This occurs as result of the process of lactogenesis that starts as early as the second trimester of pregnancy, the 16<sup>th</sup> week of 60 61 pregnancy, due to the increased levels of estrogen and progesterone in the circulation (7). 62 From day 5 up until day 7 after birth, colostrum is secreted and has a sticky consistency of 63 yellow color given by the presence of carotenes from dietary intake. Colostrum is 64 characterized by its nutritional, immunological and growth functions. The third stage is the 65 transition milk produced between days 4 and 15 after childbirth, which shows a white color 66 due to the emulsification of fats and the strong presence of calcium caseinate (7). Finally, mature milk, is produced from the 15<sup>th</sup> postpartum day looking like a thinner and diluted milk 67 68 (8). During the different maturation stages of human breast milk, a high degree of 69 interindividual differences can be expected in milk that may arise from differences in milk 70 production and possible differences in transport of the molecules and other milk components 71 like cells from blood to milk. Moreover, these differences are expected to be at least partially 72 explained by a different dietary intake of the mother. However, we still lack knowledge on 73 how diets like the Mediterranean diet, or vegetarian diets, rich in phytochemicals, might 74 influence on the content of these compounds or their metabolites in human breast milk and 75 how these might impact the health and development of the newborn.

Thousands of different dietary phytochemicals have been identified in human breast milk,
of which carotenoids and (poly)phenols (9), represent by far the largest groups (10,11). In

this study, we focused on the role of (poly)phenols such as phenolic acids, flavonoids,
stilbenes, coumarins, lignans, and tannins (Figure 1) and their host and microbial
metabolites for their well-documented protective and health-promoting properties, which
are less understood compared to carotenoids (12).

82 (Poly)phenols, a class of phytochemicals containing at least one phenolic ring, that are 83 present in large quantities in fruits and vegetables like soybeans, cocoa beans, oranges and 84 berries, as well as tea and coffee (13). They are believed to have health benefits, including 85 protection against oxidative stress and inflammation, and may decrease the risk of chronic 86 and degenerative diseases such as neurodegenerative disorders, obesity, cancer, and 87 diabetes (14-18). They are classified in flavonoids and non-flavonoids where the latter 88 include lignans, stilbenes, coumarins, tannins and simple phenolics/phenolic acids (Figure 89 1). Flavonoids represent the vast majority of (poly)phenols present in a fruit- and vegetable-90 rich diet, and include different subclasses such as: flavones, isoflavones, flavan-3-ols, 91 flavonols, flavanones and anthocyanins. These (poly)phenols have demonstrated biological 92 activities, including antioxidant and anti-inflammatory activities, consistent with the promotion 93 of vascular health, bone health, and cognitive function (14,16,19). It has been demonstrated 94 that the biological activities of all these phenolic compounds may be mediated by their 95 metabolites which are produced in vivo (host and microbial metabolites), as in the case of 96 urolithins, the ellagic acid microbial metabolites (20) and phenolic acids, the flavonoid 97 microbial metabolites (16,21).



99 Figure 1 – Chemical structures of common dietary (poly)phenols and microbiota metabolites.

100 In the figure are represented common dietary (poly)phenols like: flavonoids, lignans,

101 stilbenes, coumarins, tannins and ellagic acids. Furthermore, phenolics and phenolic acids

are present in diet and can also result from the microbiota. Meanwhile, some molecules are

103 only generated from the microbiota like urolithins from ellagic acids and 5-(phenyl)-γ-

104 valerolactones from flavan-3-ols.

### 105 2. Absorption, metabolism, and distribution of (poly)phenols

106 Owing the wide variety of (poly)phenols, like flavonoids, phenolic acids, ellagic acids, among 107 others, bioavailability varies a lot from one family to another. Some flavonoids like 108 anthocyanins, isoflavones such as genistein and daidzein and the flavanol guercetin can be 109 partially absorbed as early as in the stomach(22-25). However, most flavonoids are found in 110 foods conjugated with sugars, esterified with organic acids, and polymerized, which 111 decreases their absorption in the stomach, reaching the small intestine. In the intestine intact 112 glycosides may undergo the action of lactase phloridzin hydrolase or cytosolic β-glucosidase 113 breaking the sugar bond and releasing the respective aglycones which are subsequently 114 absorbed. (Poly)phenols that are not absorbed in the small intestine reach the colon where 115 they are transformed by the gut microbiota (Figure 2). In the case of flavonoids, they 116 undergo catabolic reaction by the gut microbiota producing the low molecular weight 117 phenolic metabolites also known by simple phenolics and phenolic acids, some of which 118 common to those found in plants and already absorbed in initial phases of digestion, like 119 benzoic acids (13,26). In fact, simple phenolics and phenolic acids present in the gut might 120 result from two distinct pathways i) directly from the intake of fruits and vegetables or ii) the 121 result of gut microbiota catabolism of flavonoids. Meanwhile, several (poly)phenols 122 metabolites can only be produced by gut microbiota. This is the case of equol, produced 123 exclusively by gut microbiota catabolism of the isoflavone daidzein, enterodiol and 124 enterolactone, produced by catabolism of lignans, 5-(phenyl)-γ-valerolactones characteristic 125 microbial metabolites of flavan-3-ols or urolithins the gut microbiota metabolites of

ellagitannins and ellagic acid (27–29). In the case of equol and urolithins the presence of specific bacteria in the microbiota of the volunteers allowed to classify them in different metabotypes (20). For equol the two metabotypes differentiate equol-producers and equolnon producers. Meanwhile for urolithins three different urolithin metabotypes exist according to the capability of gut microbiota of the host to catabolize ellagic acid. These are metabotype A: producers of urolithin A; metabotype B: producers of urolithin A and also isourolithin A and/or urolithin B, and metabotype 0: non producers of urolithins (20,30).

133 Directly after their absorption in the small intestine or in the colon, (poly)phenols and their 134 gut microbiota catabolites are extensively metabolized at both the intestinal and hepatic 135 levels. Independently of the type of (poly)phenol, all undergo phase I and II metabolic 136 reactions mediated by sulfotransferases, methyltransferases and glucuronyltransferases. 137 Once in portal circulation, (poly)phenols metabolites travel into the liver where they undergo 138 further phase I and II metabolic reactions. From the liver, (poly)phenols or their metabolites 139 may reenter the intestine through bile salts and the enterohepatic circulation (EHC) or enter 140 systemic circulation (Figure 2). In circulation, (poly)phenols metabolites spread across the 141 different organs and tissues to exert their potential biological effects or are retrained in the 142 kidneys and eliminated through urine. Importantly, several phenolic metabolites resulting 143 from dietary intake or gut microbiota catabolism of flavonoids are also produced by some 144 endogenous pathways. Some examples of molecules shared between pathways may 145 include hippuric acid, homovanillic acid and 3',4'-dihydroxyphenylacetic acid.

In lactating women, different (poly)phenols and their metabolites, mainly flavonoids, phenolic acids and ellagic acid and urolithin metabolites, have been detected in breast milk, as will be discussed ahead. These are expected to travel from blood circulation reaching the mammary glands (Figure 2), although the mechanism of transport has not been fully characterized. (Poly)phenols or their metabolites present in breast milk will start a new cycle of digestion as they will be ingested by the newborn infant. Importantly due to early stages of gut microbiota development in the infant, the amount of (poly)phenol metabolism expected in the infant is

- 153 limited in comparison with the mother, but much about the infant microbiota capability to
- 154 metabolize (poly)phenols is still unknown.



Figure 2- (Poly)phenol journey from dietary intake to breast milk in mothers and delivery the infant. (Poly)phenols are up taken from the diet reaching the gut. In the mother's gut these (poly)phenols are absorbed and potentially modified by phase I and II metabolic reactions. Meanwhile (poly)phenols may be catabolized by gut microbiota into low molecular weight phenolics that are also up taken and undergo phase I and II metabolic reactions. All these compounds reach the liver and are released into circulation where they may reach breast milk. EHC – enterohepatic circulation; SC – systemic circulation; BM – breast milk.

163

# **3. (Poly)phenolic content in Human Breast Milk**

### 165 3.1 Search strategy

First, we searched the most well-known metabolomic and/or (poly)phenolic databases regarding presence of (poly)phenols in breast milk, e.g., HMDB, phenol-explorer, phyto-hub, metabolomics workbench, among others(31–33). Overall, only HMDB reported detection and quantification of (poly)phenols in human breast milk (34). A total of 122 metabolites have been detected in human breast milk according to HMDB, mainly including amino acids, short-chain-fatty acids, sugars, and carotenoids. From this list the only (poly)phenol

172 metabolite reported was hippuric acid (34). Unfortunately, hippuric acid is also common to

173 endogenous pathways and is difficult to pinpoint its origin (endogenous versus dietary).

Afterwards, we searched PubMed for articles containing the words: "human milk" or "human breast milk" and "polyphenol" or "flavonoid". In total, we found 63 articles of which 2 were excluded due to duplication. Furthermore, 7 additional records were added since were found through other meanings (e.g., through in-text citing references). From the 68 records, 4 have been excluded since were not available in English. Furthermore, 45 articles have been excluded since they did not perform detection and/or quantification of (poly)phenols or human breast milk has not been used. (Figure 3).



181

182 Figure 3. Search strategy for the literature review and revision process

# 183 3.2 Records reporting (poly)phenol quantification

184 From the list of records found, 19 have detected and guantified dietary (poly)phenols and/or 185 metabolites in human breast milk. Of these, 12 have quantified (poly)phenols and/or 186 metabolites from dietary intervention studies (Table 1) while 7 have quantified (poly)phenols 187 and/or metabolites in free-living subjects (Table 2). Meanwhile, 15 of these 19 studies have 188 quantified flavonoids, 4 have quantified ellagic acid or urolithins metabolites, and 6 studies 189 have reported the quantification of low molecular weight phenolics (phenolic acids or simple 190 phenols), see Table 1 and Table 2. Noteworthy 4 of the 7 studies quantifying (poly)phenols 191 and/or metabolites in free-living subjects have included food-frequency questionnaires to the 192 participants of the study to monitor their diet.

193 Several studies have shown the presence of isoflavones, mainly daidzein and genistein in 194 human breast milk after dietary interventions using isoflavone rich foods like soybean milk 195 (35,36), and roasted soybean (37–39). Meanwhile other flavonoids like flavan-3-ols and their 196 microbial metabolites, 5-(phenyl)-y-valerolactones were quantified in human breast milk after 197 consumption of dark chocolate (40). Meanwhile, flavanones were detected after consumption 198 of grapefruit juice (41), flavonols after onion soup intake (42) and the ellagitannin microbial 199 metabolites, urolithins, after nuts and pomegranate consumption (20,43). In other studies, 200 several (poly)phenol compounds, including different families of flavonoids, microbial 201 metabolites, and phenolic acids, were tentatively identified in breast milk after consumption 202 of red raspberry (44), and several in free-living conditions summarized in Table 2.

As previously described, breast milk composition evolves over time while the newborn matures. Most studies have only used matured milk as the sample to detect and quantify (poly)phenols and/or metabolites (Table 1 and Table 2). Meanwhile, transition milk has only been used in four studies and colostrum in three studies, all with free-living mothers. Notably, the three studies reporting (poly)phenol and/or metabolites quantification in colostrum have also used transitional milk and mature milk as samples.

209 Khymenets *et al.* was able to quantify some epicatechin phase II conjugates (epicatechin-4-210 glucuronide, epicatechin-2-sulfate and epicatechin-3-sulfate) and several gut microbiota

211 derived metabolites like 5-(3',4'-dihydroxyphenyl)-y-valerolactone-sulfate and glucuronide 212 conjugates (40). In this study, participants were in a free-living diet condition and answer to 213 24-hour dietary recall and food frequency questionnaires showing that the total (poly)phenol 214 consumption through the diet did not significantly change during the different lactation 215 periods. However, concentrations of the detected metabolites were very sporadic and varied 216 significantly only being detected in a limited number of samples across the different lactation 217 phases. For this reason, the authors were unable to compare the changes in concentrations 218 amongst the different lactation stages.

219 Meanwhile, Sánchez-Hernández et al., showed differences in the average amount of total 220 (poly)phenols present in colostrum, transitional and matured milk, 661, 773 and 652 µg/100 221 mL respectively, of free-living individuals in comparison with infant formula, 375 µg/100 mL, 222 (9). Noteworthy, this reflects in general on a 2-fold increase in total (poly)phenol content in 223 human breast milk in comparison with formula milk (only 375 µg/100 mL), reflecting that 224 formula milk does not recapitulate complete human breast milk concerning (poly)phenol 225 content. Regarding the different stages of human breast milk, despite being a non-static fluid 226 that changes with time, no difference in total (poly)phenol content or antioxidant capacity 227 was observed among the three different types of milk.

228 In a different study Song et al., was able to quantify several flavan-3-ols (epicatechin, 229 epicatechin-gallate and epigallocatechin gallate), flavonols (quercetin and kaempferol) and 230 flavanones (naringenin and hesperitin) in breast milk samples from free-living mothers at 231 weeks 1, 4 and 13 postpartum (14). The concentrations of the those (poly)phenols did not 232 seem to change, independently of the timepoint of collection (week 1, 4 or 13), with the only 233 exception being kaempferol that significantly increased at week 13. The authors point out 234 that the levels of flavonoids during the three periods suggest that (poly)phenols in human 235 milk are generally not affected by lactation stage. Unfortunately, in this study the food intake 236 of the mothers was not evaluated and thus the estimation of (poly)phenol intake for each 237 mother was not performed. For this reason, it is possible that some of the variability in

kaempferol concentrations might be due to the food intake of the mother. In fact, from the list of studies identified, the study by Lu *et al.* was the only that fully characterized and stratified samples according to the food intake (2). For that maternal intake of plant-based foods and (poly)phenols was estimated through 3-day dietary records and the use of Phenol-Explorer database. The study concluded that the intake of plant-based foods significantly affected phenolic composition in breast milk.

244 Meanwhile Romasko et al. showed that the amount of naringenin in breast milk in free living 245 mothers with their everyday diet, resulted in an average naringenin concentration in breast 246 milk of 823.24 nmol/L (41). Upon consumption of red grapefruit juice, rich in naringenin and 247 naringin (naringenin-7-glucoside) this concentration did not significantly increase at 4 or 12 248 hours, 908.25 nmol/L  $\pm$  676.84 nmol/L, and 868.96 nmol/l  $\pm$  665.54 nmol/L, respectively. In 249 this case, the consumption of a glass of grapefruit juice did not significantly affect naringenin 250 levels in milk. Eventually the concentrations of naringenin decreased after 48 hours to 251 673.89 nmol/L. Meanwhile in a study by Jochum et al. two different interventions were used 252 and compared against a control (300 mL water) drink: i) 250 mL of soy drink or ii) 300mL of 253 decaffeinated black tea (36). Unfortunately, no flavonol was detected before or after the 254 intervention with black tea. Yet, in the soy drink group, genistein and daidzein were detected, 255 but only after the intervention.

256 The changes in values across these studies may be related to several factors. One of the 257 most important is dietary exposure to different amounts of (poly)phenols and/or foods 258 containing different/specific (poly)phenols. Dissimilarities in the dietary habits among 259 different populations could lead to high variability in the results obtained. It is very important 260 to define dietary habits during lactation to fully understand how these changes in 261 (poly)phenol and/or metabolites quantification is dependent on the mother's diet. However, 262 there is still limited information on the relationship between maternal dietary intake and 263 phenolic content in breast milk. Besides, although the concentration of the compounds is 264 dependent on the dose ingested by the mother, other regular components of the matrix such

as proteins, lipids and carbohydrates could affect the extraction and detection of these
 compounds.

267 Other important factors that could influence the detection and quantification of (poly)phenols 268 and/or metabolites in human breast milk could be the kinetic of deposition in milk, 269 interindividual differences in the metabolism and genetic/physiological factors and/or stability 270 of (poly)phenols and/or metabolites in breast milk matrix. Although with the available studies, 271 the time of milk collection has not been demonstrated to be a crucial factor, more studies 272 with large population are needed to confirm these results. The methodology for the collection of breast milk samples could also be another critical point. Most of the time the volume of 273 274 the milk produced by the mammary glands of the mothers is not measured, so the data 275 obtained from the milk analysis only provide concentrations and not the total amount 276 produced, what makes more difficult to compare among studies. Number of volunteers 277 across the 19 studies herein reported has also shown a significant pitfall on the data 278 available to researchers and clinicians. Until now only one study has used a sample size 279 equal to 50 volunteers, while most studies have used sample sizes below 30 volunteers, with 280 a significant number of studies with a sample size below 10 and some proof-of-concept/case 281 studies with sample sizes of just one or two individuals. Such sample size, together with the 282 normal interindividual variability detected in (poly)phenol bioavailability (26,45) clearly makes 283 it difficult to understand the dynamics of (poly)phenols metabolites in breast milk. Larger 284 populations are necessary to obtain final conclusions about concentrations of metabolites in 285 breast milk and factors affecting.

Differences in the methodologies used for the extraction and analysis (identification and quantification) of these compounds in breast milk also hamper the comparison among studies.

The complexity of the milk matrix partly explains why the determination of (poly)phenolderived metabolites in breast milk has hardly been investigated. Most of the methodologies are not optimized and validated and the recovery percentages of (poly)phenol metabolites

292 are usually unknown for the different extraction protocols. Most previous studies have 293 determined (poly)phenols in human milk after enzymatic hydrolysis (β-glucuronidase and 294 sulfatase) and subsequent extraction with ethyl acetate (see Table 1 and Table 2). The 295 enzymatic hydrolysis simplifies the separation and quantification of the major compounds 296 and provides an idea of the total amount of a specific aglycone (free compound plus 297 conjugated) but information about the nature of the metabolites available and the amount of 298 individual conjugated metabolites is lost. Only 5 studies provide information about naturally 299 occurring metabolites (glucuronides and sulfates) present in breast milk (40,43,44,46,47). 300 Protein precipitation with acetonitrile or methanol and solid phase extraction (SPE) were also 301 applied for the extraction of these compounds with and without previous enzymatic 302 hydrolysis. In some cases, a previous clean up with hexane was applied to defat the 303 samples and other methods to remove proteins were also used (hydrolysis with pepsin, 304 salting-out assisted liquid-liquid extraction, precipitation with organic solvents, etc.). 305 However, little information about recoveries and validation parameters was provided to 306 evaluate the results and identify the best extraction protocol for each family of compounds. 307 Only two studies have shown a comprehensive test between the different extraction 308 The data methodologies (46,48). showed that acetonitrile: formic acid (95:1) 309 extraction/protein precipitation method was the most effective method to obtain ellagic acid 310 metabolites in comparison to methanol, hexane and SPE (46). Meanwhile Edyta Nalewajko-311 Sieliwoniuk showed that hexane defat followed by acidification and ethyl acetate: acetonitrile 312 extraction was the most effective method for the extraction of several flavonoids and 313 phenolic acids (48). Unfortunately, this protocol includes the use of β-glucuronidase and 314 sulfatases. In general, it seems that ethyl acetate, which is frequently used for isolation of 315 dietary phenolic compounds, is a good solvent for the extraction of aglycones after 316 enzymatic hydrolysis. However, when more polar compounds such as glucuronide and 317 sulfate conjugates are extracted, the recoveries are low and other protocols based of 318 precipitation of protein with organic solvents or solid phase extraction should be used.

Another question that could affect the extraction and analysis of compounds in the different studies is the nature of the milk (content of protein and lipids) that could affect the extraction protocol with the formation of gel aggregates or the precipitation of some compounds.

Besides, the way of quantification is another important question that could influence the results in the different studies. In most cases the absence of commercial standards forces to quantify using other available standards, obtaining inaccurate results not comparable among studies.

### 326 **3.3 Detected and quantified (poly)phenols in human breast milk**

327 Across the 19 records reporting (poly)phenols and metabolites in human breast milk a total 328 of 25 flavonoids, 58 low molecular weight phenolics and 9 ellagic acid metabolites were 329 detected (Figure 4, Table 3-5). The list of flavonoids included the most representative 330 subfamilies of flavonoids: anthocyanins, flavonols, flavan-3-ols, isoflavones and flavanones 331 (Table 3, Figure 4). Interestingly besides sulfate and glucuronide conjugates some flavonoid 332 glycoside conjugates have been found in human breast milk (Table 3). From the 9 ellagic 333 acid metabolites, urolithin A, isourolithin A and urolithin B and respective sulfate and 334 glucuronide metabolites were reported together with dimethyl ellagic acid-glucuronide, but 335 not ellagic acid (Table 4, Figure 4). Regarding the low molecular weight phenolics detected, 336 these ranged from benzoic acids, benzaldehydes, phenylacetic acids, 3-(phenyl)propanoic 337 acids, cinnamic acids, 5-(phenyl)-y-valerolactones, hippuric acids and chlorogenic acid 338 (Table 5, Figure 4). Anthocyanins, isoflavones, flavanones and ellagic acid metabolites have 339 not been detected in all types of milk, by contrast with the remaining (poly)phenolic classes 340 that have been detected across all the different types of milk (colostrum, transitional and 341 mature). It is however important to note that most studies have used one type of milk only, 342 mature milk, thus explaining why several (poly)phenols have been detected in only one milk 343 type.



345 Figure 4- Ninety-two (poly)phenols and metabolites have been identified and/or quantified in 346 human breast milk samples across the 19 reports identified. (A) From the overall list of compounds 347 58 were low molecular weight (LMW) phenolics, 9 ellagic acid metabolites, and 25 flavonoids. (B) 348 The 25 flavonoids spread across flavan-3-ols, anthocyanins, flavonols, isoflavones and flavanones. (C) 349 The low molecular weight phenolics and their phase II conjugates are divided into benzoic acids, 350 cinnamic acids, 5-phenyl-γ-valerolactones, phenylacetic acids, benzaldehydes, 3-(phenyl)propanoic 351 acids, hydroxybenzenes, hippuric acids and chlorogenic acid. (D) The 9 ellagic acids and/or 352 metabolites and their phase II conjugates are divided into 8 urolithin metabolites and 1 ellagic acid 353 metabolites. Individual concentrations for each (poly)phenol are reported in tables 3, 4, and 5.

354

355 Among the flavan-3-ols, commonly found in chocolate(49), epigallocatechin-gallate was the 356 molecule detected at highest concentrations in breast milk, ranging from 0.67 to 1.12µM 357 (Figure 5A, Table 3). In previously reported intervention studies, reviewed in (50), this 358 molecule was detected in plasma, on average, at much lower concentrations, ranging from 359 0.03 to 0.38µM(50). Meanwhile, a more recent review shown higher plasma concentrations 360 with a mean Cmax across several studies of  $0.87 \pm 1.33 \mu$ M, on par with breast milk 361 concentrations(51). By contrast, other flavan-3-ols like (epi)catechin, was detected at higher 362 concentration in plasma ranging from 0.09 to 1.10µM, in comparison to breast milk of 0.03 to 363 0.24µM(50). Meanwhile, quercetin was the flavonol detected in highest concentrations in 364 human breast milk ranging from 0.05 to 0.15µM (Figure 5B, Table 3). Remarkably in the 365 study performed by Zhang et al. 2018 measuring guercetin in both breast milk and plasma of 366 the mothers, it was shown that quercetin was more abundant in breast milk and urine in 367 comparison with plasma(44).

Regarding the flavanones naringenin and hesperidin, commonly found in citric fruits(49),
have been detected in plasma at concentrations ranging from 0.13 to 1.50µM and 0.21 to
0.87µM respectively (Figure 5C, Table 3). Meanwhile, in breast milk both flavanones have

been detected at lower concentrations ranging between 0.01 to 0.91µM for naringenin and from 0.004 to 0.46µM for hesperidin (Table 3). Regarding isoflavones, daidzein and genistein have been found in plasma ranging from 0.76 to 3.00µM and 1.26 to 4.50µM, respectively(50). Meanwhile, in breast milk these two isoflavonoids have been found in much lower concentrations ranging from 0.009 to 0.10µM and 0.005 to 0.12µM respectively (Figure 5C, Table 3).

The urolithin metabolites urolithin A-glucuronide and urolithin B-glucuronide were the two most abundant ellagic acid metabolites found in breast milk at  $0.03\mu$ M and  $0.02\mu$ M respectively (Figure 5D, Table 4). In plasma these two metabolites have been found at identical concentrations of  $0.02\mu$ M, similar to those of breast milk(52). On the opposite direction, urolithin A-sulfate detected in breast milk ranging from 0.008 to  $0.02\mu$ M (Figure 5, Table 4), was detected at much higher concentrations in plasma of  $0.45\mu$ M(52).

383 Meanwhile, a recent literature review revealed the full list of low molecular weight phenolic 384 metabolites present in human blood(26). From this list of 137 phenolic metabolites detected in human blood, only 58 have been detected and or quantified in human breast milk (Table 385 386 5). Most of these metabolites have been found in significantly higher concentrations in 387 human plasma in comparison with human breast milk. For example, regarding the phenolic 388 acid 3,4-dihydroxybenzoic acid and benzaldehyde 3,4-dihydroxybenzaldehyde, these have 389 been found in breast milk at concentrations ranging from 0.01 to 0.02µM and 0.009 to 390 0.01µM (Figure 5E, Table 5). While in plasma, these metabolites have been found up to 391 16µM and 0.03µM respectively. Meanwhile, 4-hydroxyphenyl acetic acid, 4-hydroxy-3-392 methoxycinnamic acid (ferulic acid) and 3-methoxycinnamic acid-4-glucuronide (ferulic acid-393 glucuronide) have been found in breast milk up to 0.27µM, 0.13µM and 0.3µM respectively 394 (Figure 5F and Table 5). Whereas in plasma these have been found at 2.6µM, 0.42µM and 395 0.36µM respectively. Noteworthy, the metabolite detected at higher concentrations in human 396 breast milk was 3.4.5-trihydroxybenzoic acid with a range of 0.06 to 0.66  $\mu$ M (Figure 5E. 397 Table 5) detected to a lesser extent in plasma  $0.12 \pm 0.032 \mu$ M, reviewed in (26).



Figure 5 – Range of concentrations of (poly)phenols detected in human breast milk. (A) flavan-3-ols,
(B) flavonols, (C) flavanones and isoflavones, (D) ellagic acid metabolites, (E) benzoic acids and
benzaldehydes, (F) phenylacetic, cinnamic acids, chlorogenic acids and phenyl-γ-valerolactones.
Each dot represents the different concentrations reported in Tables 3, 4 and 5. Val – valeric acid; gluc
– glucuronide.

405

406 Interestingly several classes of low molecular weight phenolics have not been detected in 407 human breast milk. This may be related with the lack of standards and/or a target analysis 408 excluding quantification of several metabolites, or the complete absence of this metabolites 409 in human breast milk. Examples of such metabolites not detected in human breast milk are : 410 2-(phenyl)propanoic acid, mandelic acid, cinnamoylglycine, 4-hydroxy-5-(phenyl)valeric acid, 411 5-(phenyl)valeric acid, (phenyl)ethanol or 4-ethylbenzenes. Regarding ellagic acid 412 metabolites, besides the 9 ellagic acid metabolites found in human breast milk and found in blood, others have been found in human blood but not in human breast milk, namely urolithin 413 414 C, urolithin C glucuronide and urolithin C sulfate (34).

415 Overall, several reasons might explain the discrepancy between the number of (poly)phenols 416 detected in blood versus human breast milk. Noteworthy the data obtained for plasma and 417 breast milk samples have been obtained from different populations with probably differences 418 in the dietary exposure of (poly)phenols and in the absorption and metabolism of these 419 compounds. A particular relevant question is the possible changes on the metabolism of 420 (poly)phenols of recent post-partum volunteer. Large studies quantifying (poly)phenols in 421 both plasma and breast milk of the same volunteer are required comparing concentrations in 422 both fluids and addressing this possibility. In the paper of Zhang et al., most of the identified 423 metabolites were detected in the three biological samples (plasma and urine of two 424 volunteers and breast milk of another volunteer) and some were present in urine and breast 425 milk but not in plasma. This may reflect some intrinsic physical chemical property of each 426 compound to either stay in plasma or being rapidly eliminated from blood and accumulate in

427 urine and breast milk. Other factors could be i) their absence from human breast milk due to 428 the lack of specific transporters impairing their path through the mammary tissue, ii) the 429 timepoints used for the sampling and further quantification of the (poly)phenols metabolites 430 in the milk iii) lower concentrations in human breast milk (below limit of quantification) in 431 comparison with the already reported in circulation, iv) the fact these (poly)phenols 432 metabolites have never been searched in human breast milk due to the lack of available 433 standards, v) the extraction method is not fully compatible to all (poly)phenol metabolites.

434 One unsolved question that its understanding can shed light to some of these questions is 435 the mechanism of transport allowing (poly)phenols and/or metabolites to reach human 436 breast milk. The transport and delivery of (poly)phenols to the mammary glands is still 437 unknown and may result from passive diffusion, active transport, or carrier mediated 438 transport. For flavonoids, several methods of transport have been proposed to cross several 439 tissues like the gut from passive diffusion to mediated transport, especially by ATP-binding 440 cassette transporter (ABC transporters) and organic acid transporters (OAT), reviewed in 441 (53). For phenolic metabolites it is hypothesized that passive transport might be the main 442 route of transport across the tissue, although some transporters have already been 443 described. These include gallic acid through OAT3 (54) and homovanillic acid through 444 rOAT3 (55). Interestingly homovanillic acid is both an endogenous molecule, a metabolite of 445 dopamine and a phenolic metabolite result of microbiota catabolism of flavonoids. Other 446 phenolic metabolites that also result from endogenous pathways like hippuric acid and 2-447 (3,4-dihydroxyphenyl)acetic acid (DOPAC) that might benefit from the endogenous routes of 448 transport. Furthermore, it also offers the possibility that structurally similar phenolics might 449 share the same routes.

450

451

# 4 The potential health benefits of (poly)phenols and phenolic metabolites in human 453 breast milk

Although multiple studies have reported the protective effects of (poly)phenols against inflammation, oxidative stress and cardiometabolic stress, and the potential of isoflavones as phytoestrogens, the full spectrum of effects of (poly)phenols in human breast milk, both from the mother and the newborn perspective, has not been fully explored. Across the different studies reported in the literature the evaluation of the impact of (poly)phenols detected in human breast milk have been rather limited to the anti-oxidative properties of milk or the quantification of phytoestrogens and its impact on the newborn development.

461 Regarding the anti-oxidative properties of (poly)phenols in human breast milk Poniedzialek 462 et al., showed that an increase in total (poly)phenols in human breast milk associated with a 463 higher total antioxidant capacity that were positively correlated with vegetable consumption 464 (56). Total (poly)phenols also correlated negatively with malondialdehyde content. 465 Noteworthy it is important to bring attention to the high degree of variability of samples 466 collected. Li et al., compared the total (poly)phenol content in samples from breast milk and 467 infant formula. In this case no significant change was detected as the variability within breast 468 milk and infant formulas was significant (422 - 751 mg/kg and 329 - 797 mg/kg of ferulic 469 acid equivalents respectively) (57).

470 A different study by Silberstein *et al.*, showed that the (poly)phenolic content in breast milk 471 seems to be influenced by maternal health status (58). The study has shown that the breast 472 milk composition of preeclampsia women presents a 33% increase in total (poly)phenol 473 content in comparison with healthy women (58). The increase in total (poly)phenols in 474 mothers with preeclampsia was associated with a reduction in about 20% the levels of lipid 475 oxidation in colostrum in comparison with healthy women (58). Unfortunately, the authors 476 only measured the total amount of (poly)phenols and did not investigate the presence or 477 effects of specific (poly)phenols or their metabolites.

Concerning isoflavones, these have been classified as phytoestrogen for their chemical similarity with estradiol and the capability to induce estrogenic or anti-estrogenic effects depending on the dose (59). Isoflavones as phytoestrogens bind to estrogen receptors alpha and beta (59). Isoflavones are present across several fruits and legumes with significant relevance in soybeans and soy-based produces like soy milk and tofu. For their capability to act as phytoestrogens, soy and soy-based products have been used in infant formulas in the last century and their effects analyzed.

485 Setchell et al., compared the presence of isoflavones in 4-month-old infant blood samples 486 consuming human breast milk, soy-based infant formulas, and cow-based milk formulas 487 (60). The concentration of isoflavones circulating in babies fed with human breast milk was 488 on average 4.7 ug/L in comparison with the 9.4 ug/L of cow-based infant formula and the 489 979.7 ug/L of soy-based formula. This high plasma isoflavones concentrations in infants 490 consuming soy-based formula are however much higher than the normal estradiol 491 concentrations for infants of this age. One phenomenon detected was the lack of isoflavones 492 metabolites, namely equol and its metabolites, from soy-based infant formula since the 493 formation of this metabolites are largely dependent on the gut microbiota of the mother (60).

Meanwhile, Rosa et al. also showed a significant difference on the urinary phenolic metabolites of 3-month-old infants feed with breast milk, cow-based infant formula, and soybased infant formula (61). In this study the overall quantity of phenolic metabolites excreted in infant urine was 2-fold higher for some metabolites, namely 3'-hydroxyphenylacetic acid and 4'-hydroxyphenylacetic acid in infants feed with soy-based infant formula in comparison with human breast milk feed infants (61).

Although the evidence suggests an increase of isoflavones levels in infants fed with soybased formulas there is no clear evidence of a health benefit. In fact, a meta-analysis could not find any negative effects of a high isoflavone intake from soy formulas, but also no benefits, on endocrine and other physiological functions of breastfeeding (62). The authors

speculated that most isoflavones detectable in the plasma of soy fed infants are conjugated
to sugars, which cannot link to isoflavone receptors.

506 Regarding the cognitive developmental status of infants, Andres et al., 2012 evaluated 1 507 year old infants consuming breast milk, cow-based milk formula or soy-based milk formula. 508 In this study infants were assessed using Bayley Scales of Infant Development (BSID), from 509 which the Mental Developmental Index (MDI) and Psychomotor Development Index (PDI) 510 were derived (63). Small but statistically significant effects of the diet on the MDI scores 511 were seen for infants 6 months or older. Breastfed infants had significantly higher scores 512 than soy fed infants at ages 6, 9, and 12 months and significantly higher scores than cow-513 based milk fed infants at ages 9 and 12 months. Although these effects reached statistical 514 significance, the MDI scores were within the expected normal range, and the differences 515 were very small. Significant effects of the diet on the PDI scores were transient. Soy fed 516 infants had significantly lower PDI scores, although small, compared with breastfed infants, 517 and seen only at 6 months. Furthermore, infants were also assessed with the Preschool 518 Language Scale-3 (PLS-3) by using the expressive communication and auditory 519 comprehension subscales. In PLS-3, only cow-based milk fed infants had significantly lower 520 scores compared with breastfed infants at ages 3 and 6 months, but again all groups were 521 inside the normal range (63).

522 Ostrom et al., also observed the immune status of infants fed with soy-based formulas and 523 human milk/infant formula feed infants (64,65). In this study infants were immunized against 524 Haemophilus influenzae type b polysaccharide, diphtheria toxoid, tetanus toxoid, and oral 525 poliovirus of children and their responses evaluated at 6, 7 and 12 months of age. Antibodies 526 against H. influenzae type b at 7 and 12 months were higher significantly higher in infants 527 fed with soy-based milk (65). In contrast, human milk/infant formula fed infants had higher 528 poliovirus neutralizing antibodies at 12 months of age. Serum IgG and IgA levels were 529 similar between groups as well as morbidly through the first year of life. Only physician-530 reported diarrhea was different between groups fed with human milk/infant formula having

Iess cases than the soy group (65). Latter Cordle et al., with the same cohort showed that the number and percentage of B, T and NK lymphocytes were within age-related normal ranges with minor differences between soy formula and human milk/infant formula fed infants (64). Overall, no differences were detected between the two groups due to soybased formulas consumption suggesting normal immune system development.

536

### 537 5. Conclusions and future perspectives

538 In this literature search we have listed the (poly)phenols and their metabolites, namely 539 flavonoids, ellagic acids and phenolics detected in human breast milk. Nonetheless, the 540 information available in the literature about the presence of (poly)phenols and/or their 541 metabolites reported in human breast milk is still in its infancy and requires further studies. 542 Many (poly)phenols and their metabolites have been detected in human circulation (26), yet 543 their presence in human milk have not been fully explored, due to several factors mentioned 544 before. Meanwhile, several nuances in the design of the studies performed may be hindering 545 the identification and their quantification in breast milk such as the timepoint of collection, 546 volume, extraction and method of quantification that may still require further optimizations.

547 Concentrations of some (poly)phenol and their metabolites in human breast milk may be 548 dependent on the diet of the mother, demonstrated by some intervention studies using 549 (poly)phenols rich foods or the stratification of volunteers. This type of pattern has also been 550 observed, with an increase in sugar and fat in human breast milk after mother ingested 551 sugar and fat enriched diets (66). The type of milk (colostrum, transitional or mature) did not 552 seem to make an impact in the quantification of some (poly)phenols. Several factors may still 553 require further investigation such as mother's interindividual differences (genetic, metabolic, 554 microbiota) or even variations caused by the circadian rhythm on breast milk composition 555 (66). In fact, most studies have not reported the time of collection and volume of breast milk, 556 which may be a big limitation, as milk production and composition may vary according to the

557 mothers and child dietary needs across the day. Some of the mentioned studies have 558 managed this issue by assuring the collection of the full content of breast milk, choosing a 559 specific time of the day for collection of all volunteers. Notwithstanding, information on how 560 (poly)phenol composition varies on breast milk during the day is still nonexistent. 561 Additionally, most studies have used small sample sizes that may overlook interindividual 562 differences. Further studies addressing these issues may give a better insight on the 563 presence of (poly)phenols and/or their metabolites in human breast milk and the impact of 564 diets like the Mediterranean diet, vegetarian diet or vegan diets on the compounds present in 565 human milk.

566 The studies on the potential health benefits to the infant of mother's (poly)phenols 567 consumption and their presence in breast milk have been limited. The anti-oxidative 568 properties of breast milk as function of total (poly)phenols have been performed, yet these 569 should be looked has rather rough indicators. Measurement of general markers of 570 antioxidant status, such as ORAC, TRAP, FRAP and TEAC are inappropriate methods for 571 clinical studies because of the broad range of compounds (e.g., uric acid, albumin) that may 572 interfere with the results of these analyses (67,68). More suitable markers for the increased 573 cellular antioxidant potential may include nuclear Nrf-2 DNA binding capacity and NQO1 574 protein levels, which were observed to increase following (poly)phenol intake and not 575 following a challenge meal alone (69).

576 The presence of phytoestrogens like isoflavones in human breast milk has been studied due 577 to their potential to mimic estrogens. Several studies have focused on the comparison 578 between human breast milk and soy-based infant formulas rich in isoflavones. Nonetheless, 579 no clear conclusion has been reached about the potential health benefit of soy-based milk. 580 Although (poly)phenols have been known for their anti-inflammatory properties, until now 581 only one study has focused on the immunity of the infant and the presence of (poly)phenols 582 in the breast milk (64). Newborns and especially pre-term infants can suffer from severe 583 inflammatory conditions yet our knowledge of (poly)phenols impact in these conditions is

584 lacking as this study has never been addressed. Overall, there are clear gaps in our current 585 knowledge concerning what metabolites from dietary (poly)phenols appear in human breast 586 milk and their quantification. Moreover, this hampers our understanding of their potential 587 health benefits for the infant. At the present date the scientific data on the health potential of 588 (poly)phenols in adults is vast, yet very little is known about their effect in infants that 589 received them through milk. It will be important to design studies that make it possible to 590 relate the milk composition in (poly)phenol metabolites with infant's health outcomes. Our 591 understanding of the potential health benefits of mother's diets rich in (poly)phenols for the 592 newborn have a huge potential to help clinicians to deal with such a fragile phase of life of 593 infants with health complications. This will open a new way for the mothers to provide the 594 conditions for a strong and healthy growth of their child.

595

### 596 6. Acknowledgments

The authors gratefully acknowledge the support given by Doctor Teresa Costa regarding the literature search process. This work has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program under grant agreement No 804229. INOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344). Authors would also like to acknowledge FCT for financial support of D.C. (2020.04630.BD).

603

### 604 **7. Author contributions**

Diogo Carregosa: Conceptualization; Data curation; Formal analysis; Investigation;
Methodology; Resources; Software; Visualization; Writing – original draft. Inês P. Silva:
Data curation; Formal analysis; Investigation; Methodology; Resources; Software;
Visualization; Writing – original draft. Carolina Teixeira: Data curation; Formal analysis;
Investigation; Methodology; Resources; Software; Visualization; Writing – original draft.

610	Mariana Baltazar: Data curation; Formal analysis; Investigation; Methodology; Resources;
611	Software; Visualization; Writing – original draft. Rocio García-Villalba: Formal analysis;
612	Supervision; Validation; Visualization; Writing - original draft; Writing - review & editing.
613	Filipa Soares Vieira: Validation; Visualization; Writing – review & editing. Mónica Marçal:
614	Validation; Visualization; Writing - review & editing. Madalena Tuna: Formal analysis;
615	Supervision; Validation; Visualization; Writing - original draft; Writing - review &
616	editing. Cláudia Nunes dos Santos: Conceptualization; Data curation; Formal analysis;
617	Project administration; Supervision; Writing – review & editing

618

# 619 8. References

620	1.	Cortez MV, Soria EA. The Effect of Freeze-Drying on the Nutrient, Polyphenol, and
621		Oxidant Levels of Breast Milk. Breastfeeding Medicine. Mary Ann Liebert Inc.; 2016. p.
622		551–4.
623	2.	Lu Z, Chan Y-T, Lo KK-H, Wong VW-S, Ng Y-F, Li S-Y, Ho W-W, Wong M-S, Zhao D.
624		Levels of polyphenols and phenolic metabolites in breast milk and their association
625		with plant-based food intake in Hong Kong lactating women. Food Funct
626		2021;12:12683–95.
627	3.	Collado MC, Delgado S, Maldonado A, Rodríguez JM. Assessment of the bacterial
628		diversity of breast milk of healthy women by quantitative real-time PCR. Lett Appl
629		Microbiol 2009;48:523–8.
630	4.	Valls-Bellés V, Abad C, Hernández-Aguilar MT, Nacher A, Guerrero C, Baliño P, Romero
631		FJ, Muriach M. Human Milk Antioxidative Modifications in Mastitis: Further Beneficial
632		Effects of Cranberry Supplementation. Antioxidants 2021;11:51.

633	5.	Geneva: World Health Organization. Guideline: Counselling of women to improve
634		breastfeeding practices . Licence: CC BY-NC-SA 30 IGO 2018;
635	6.	Lorenzetti S, Plösch T, Teller IC. Antioxidative Molecules in Human Milk and
636		Environmental Contaminants. Antioxidants 2021;10:550.
637	7.	Pillay J, Davis TJ. Physiology, Lactation. 2022.
638	8.	Ríos J, Valero-Jara V, Thomas-Valdés S. Phytochemicals in breast milk and their
639		benefits for infants. Critical Reviews in Food Science and Nutrition. Bellwether
640		Publishing, Ltd.; 2021.
641	9.	Sánchez-Hernández S, Esteban-Muñoz A, Samaniego-Sánchez C, Giménez-Martínez R,
642		Miralles B, Olalla-Herrera M. Study of the phenolic compound profile and antioxidant
643		activity of human milk from Spanish women at different stages of lactation: A
644		comparison with infant formulas. Food Research International 2021;141:110149.
645	10.	Ríos J, Valero-Jara V, Thomas-Valdés S. Phytochemicals in breast milk and their
646		benefits for infants. Crit Rev Food Sci Nutr 2022;62:6821–36.
647	11.	Tsopmo A. Phytochemicals in Human Milk and Their Potential Antioxidative
648		Protection. Antioxidants 2018;7:32.
649	12.	Slavin JL. Phytoestrogens in breast milkanother advantage of breast-feeding? Clin
650		Chem 1996;42:841-2.
651	13.	del Rio D, Rodriguez-Mateos A, Spencer JPE, Tognolini M, Borges G, Crozier A. Dietary
652		(Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of
653		Protective Effects Against Chronic Diseases. Antioxid Redox Signal [Internet] Mary Ann
654		Liebert Inc; 2013;18:1818–92. Available from:
655		http://www.liebertpub.com/doi/10.1089/ars.2012.4581

656	14.	Song BJ, Jouni ZE, Ferruzzi MG. Assessment of phytochemical content in human milk
657		during different stages of lactation. Nutrition 2013;29:195–202.
658	15.	Hussain T, Tan B, Yin Y, Blachier F, Tossou MCB, Rahu N. Oxidative Stress and
659		Inflammation: What Polyphenols Can Do for Us? Oxid Med Cell Longev 2016;2016:1-
660		9.
661	16.	Carregosa D, Mota S, Ferreira S, Alves-Dias B, Loncarevic-Vasiljkovic N, Crespo CL,
662		Menezes R, Teodoro R, Santos CN dos. Overview of Beneficial Effects of (Poly)phenol
663		Metabolites in the Context of Neurodegenerative Diseases on Model Organisms.
664		Nutrients 2021;13:2940.
665	17.	Raimundo AF, Félix F, Andrade R, García-Conesa M-T, González-Sarrías A, Gilsa-Lopes
666		J, do Ó D, Raimundo A, Ribeiro R, Rodriguez-Mateos A, et al. Combined effect of
667		interventions with pure or enriched mixtures of (poly)phenols and anti-diabetic
668		medication in type 2 diabetes management: a meta-analysis of randomized controlled
669		human trials. Eur J Nutr 2020;59:1329–43.
670	18.	Zhou Y, Zheng J, Li Y, Xu D-P, Li S, Chen Y-M, Li H-B. Natural Polyphenols for Prevention
671		and Treatment of Cancer. Nutrients 2016;8:515.
672	19.	Santos CN, Gomes A, Oudot C, Dias-Pedroso D, Rodriguez-Mateos A, Vieira HLA,
673		Brenner C. Pure Polyphenols Applications for Cardiac Health and Disease. Curr Pharm
674		Des 2018;24:2137–56.
675	20.	García-Villalba R, Giménez-Bastida JA, Cortés-Martín A, Ávila-Gálvez MÁ,
676		Tomás-Barberán FA, Selma MV, Espín JC, González-Sarrías A. Urolithins: a
677		Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut
678		Microbiota. Mol Nutr Food Res 2022;66:2101019.

679	21.	Carregosa D,	Carecho RM,	Figueira I	, Santos CN. I	Low molecula	r weight	metabolites
-----	-----	--------------	-------------	------------	----------------	--------------	----------	-------------

- 680 from polyphenols as effectors for attenuating neuroinflammation. J Agric Food Chem
- 681 [Internet] 2019;acs.jafc.9b02155. Available from:
- 682 http://pubs.acs.org/doi/10.1021/acs.jafc.9b02155
- 683 22. Crespy V, Morand C, Besson C, Manach C, Demigne C, Remesy C. Quercetin, but not Its
  684 Glycosides, Is Absorbed from the Rat Stomach. J Agric Food Chem 2002;50:618–21.
- Passamonti S, Vrhovsek U, Vanzo A, Mattivi F. The stomach as a site for anthocyanins
  absorption from food <sup>1</sup>. FEBS Lett 2003;544:210–3.
- 587 24. Talavéra S, Felgines C, Texier O, Besson C, Lamaison J-L, Rémésy C. Anthocyanins Are
  588 Efficiently Absorbed from the Stomach in Anesthetized Rats. J Nutr 2003;133:4178–82.
- Piskula MK, Yamakoshi J, Iwai Y. Daidzein and genistein but not their glucosides are
  absorbed from the rat stomach. FEBS Lett 1999;447:287–91.
- 69126.Carregosa D, Pinto C, Ávila-Gálvez MÁ, Bastos P, Berry D, Santos CN. A look beyond692dietary (poly)phenols: The low molecular weight phenolic metabolites and their
- 693 concentrations in human circulation. Compr Rev Food Sci Food Saf 2022;21:3931–62.
- Tomás-Barberán FA, García-Villalba R, González-Sarrías A, Selma M v., Espín JC. Ellagic
   Acid Metabolism by Human Gut Microbiota: Consistent Observation of Three Urolithin
   Phenotypes in Intervention Trials, Independent of Food Source, Age, and Health
   Status. J Agric Food Chem 2014;62:6535–8.
- Mena P, Bresciani L, Brindani N, Ludwig IA, Pereira-Caro G, Angelino D, Llorach R,
  Calani L, Brighenti F, Clifford MN, et al. Phenyl-γ-valerolactones and phenylvaleric
  acids, the main colonic metabolites of flavan-3-ols: synthesis, analysis, bioavailability,
  and bioactivity. Nat Prod Rep [Internet] Royal Society of Chemistry ({RSC}); 2019;
  Available from: http://xlink.rsc.org/?DOI=C8NP00062J

703		29.	Heinonen S-M, Hoikkala A, Wähälä K, Adlercreutz H. Metabolism of the soy
704			isoflavones daidzein, genistein and glycitein in human subjects. J Steroid Biochem Mol
705			Biol [Internet] Elsevier {BV}; 2003;87:285–99. Available from:
706			https://linkinghub.elsevier.com/retrieve/pii/S096007600300414X
707		30.	Tomás-Barberán FA, González-Sarrías A, García-Villalba R, Núñez-Sánchez MA, Selma
708			M v., García-Conesa MT, Espín JC. Urolithins, the rescue of "old" metabolites to
709			understand a "new" concept: Metabotypes as a nexus among phenolic metabolism,
710			microbiota dysbiosis, and host health status. Mol Nutr Food Res 2017;61:1500901.
711	31.	Rothw	ell JA, Perez-Jimenez J, Neveu V, Medina-Remon A, M'Hiri N, Garcia-Lobato P, Manach
712		C, Kno	x C, Eisner R, Wishart DS, et al. Phenol-Explorer 3.0: a major update of the Phenol-
713		Explor	er database to incorporate data on the effects of food processing on polyphenol
714		conter	nt. Database [Internet] Oxford University Press ({OUP}); 2013;2013. Available from:
715		https:/	//academic.oup.com/database/article-lookup/doi/10.1093/database/bat070
716	32.	da Silv	a A, Giacomoni F, Pavot B, Fillâtre Y, Rothwell JA, Sualdea BB, Veyrat C, Garcia-Villalba
717		R, Glad	dine C, Kopec R, et al. PhytoHub V1. 4: A new release for the online database dedicated
718		to foo	d phytochemicals and their human metabolites. Proceedings of the 1st International
719		Confei	rence on Food Bioactivities & Health, Norwich, UK. 2016. p. 13–5.
720	33.	Sud M	, Fahy E, Cotter D, Azam K, Vadivelu I, Burant C, Edison A, Fiehn O, Higashi R, Nair KS, et
721		al. Me	tabolomics Workbench: An international repository for metabolomics data and
722		metad	ata, metabolite standards, protocols, tutorials and training, and analysis tools. Nucleic
723		Acids I	Res 2016;44:D463–70.
724	34.	Wisha	rt DS, Guo A, Oler E, Wang F, Anjum A, Peters H, Dizon R, Sayeeda Z, Tian S, Lee BL, et
725		al. HM	DB 5.0: the Human Metabolome Database for 2022. Nucleic Acids Res 2022;50:D622–
726		31.	

727 33. Lind W, Wall, Walls Q, Lind A, Lind S, Walls T, Walls T, Noil Z, El H, Ells T, Cl	., Zhang Y, Wu W, Wang Y, Ren Z, Li H, Ling Y, et al.	/, Wu W, Wa	, Zhou X, Zhang Y	WuH, Wang C	Zhou W	35.	727
---	---	-------------	-------------------	-------------	--------	-----	-----

- 728 Simultaneous determination of formononetin, biochanin A and their active metabolites in
- 729 human breast milk, saliva and urine using salting-out assisted liquid-liquid extraction and
- 730 ultra high performance liquid chromatography-electrospray ionization tandem mass
- 731 spectrum. Journal of Chromatography B 2020;1145:122108.
- 732 36. Jochum F, Alteheld B, Meinardus P, Dahlinger N, Nomayo A, Stehle P. Mothers' Consumption
- 733 of Soy Drink But Not Black Tea Increases the Flavonoid Content of Term Breast Milk: A Pilot
- Randomized, Controlled Intervention Study. Ann Nutr Metab 2017;70:147–53.
- 735 37. Franke AA, Custer LJ. Daidzein and genistein concentrations in human milk after soy
- 736 consumption. Clin Chem 1996;42:955–64.
- 737 38. Franke AA, Custer LJ, Tanaka Y. Isoflavones in human breast milk and other biological fluids.
  738 Am J Clin Nutr 1998;68:1466S-1473S.
- 39. Franke AA, Custer LJ, Wang W, Shi CY. HPLC Analysis of Isoflavonoids and Other Phenolic

Agents from Foods and from Human Fluids. Exp Biol Med 1998;217:263–73.

- 40. Khymenets O, Rabassa M, Rodríguez-Palmero M, Rivero-Urgell M, Urpi-Sarda M, Tulipani S,
- 742 Brandi P, Campoy C, Santos-Buelga C, Andres-Lacueva C. Dietary Epicatechin Is Available to
- 743 Breastfed Infants through Human Breast Milk in the Form of Host and Microbial Metabolites.
- 744 J Agric Food Chem 2016;64:5354–60.
- 745 41. Romaszko E, Marzec-Wróblewska U, Badura A, Buciński A. Does consumption of red
- 746 grapefruit juice alter naringenin concentrations in milk produced by breastfeeding mothers?
  747 PLoS One 2017;12:e0185954.
- Romaszko E, Wiczkowski W, Romaszko J, Honke J, Piskula MK. Exposure of breastfed infants
  to quercetin after consumption of a single meal rich in quercetin by their mothers. Mol Nutr
  Food Res 2014;58:221–8.

751	43.	Henning SM, Yang J, Lee R-P, Huang J, Thames G, Korn M, Ben-Nissan D, Heber D, Li Z.
752		Pomegranate juice alters the microbiota in breast milk and infant stool: a pilot study. Food
753		Funct 2022;13:5680–9.
754	44.	Zhang X, Sandhu A, Edirisinghe I, Burton-Freeman B. An exploratory study of red raspberry (
755		Rubus idaeus L.) (poly)phenols/metabolites in human biological samples. Food Funct
756		2018;9:806–18.
757	45.	Feliciano RP, Boeres A, Massacessi L, Istas G, Ventura MR, Nunes dos Santos C, Heiss C,
758		Rodriguez-Mateos A. Identification and quantification of novel cranberry-derived plasma and
759		urinary (poly)phenols. Arch Biochem Biophys [Internet] Elsevier {BV}; 2016;599:31–41.
760		Available from: https://linkinghub.elsevier.com/retrieve/pii/S0003986116300145
761	46.	Cortés-Martín A, García-Villalba R, García-Mantrana I, Rodríguez-Varela A, Romo-Vaquero M,
762		Collado MC, Tomás-Barberán FA, Espín JC, Selma MV. Urolithins in Human Breast Milk after
763		Walnut Intake and Kinetics of Gordonibacter Colonization in Newly Born: The Role of
764		Mothers' Urolithin Metabotypes. J Agric Food Chem 2020;68:12606–16.
765	47.	Henning SM, Wallenstein MB, Weigel N, Johnson C, Yang J, Lee R-P. Appearance of Ellagic
766		Acid Metabolites from Pomegranate Juice in Breast Milk: A Case Report. Ann Clin Case Rep
767		2019;4:1738.
768	48.	Nalewajko-Sieliwoniuk E, Hryniewicka M, Jankowska D, Kojło A, Kamianowska M, Szczepański
769		M. Dispersive liquid-liquid microextraction coupled to liquid chromatography tandem mass
770		spectrometry for the determination of phenolic compounds in human milk. Food Chem
771		2020;327:126996.
772	49.	Pinto P, Santos CN. Worldwide (poly)phenol intake: assessment methods and identified gaps.
773		Eur J Nutr 2017;56:1393–408.

- 774 50. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review
- of 93 intervention studies. Am J Clin Nutr [Internet] Oxford University Press ({OUP});
- 776 2005;81:243S-255S. Available from:
- 777 https://academic.oup.com/ajcn/article/81/1/243S/4607529
- 778 51. di Pede G, Mena P, Bresciani L, Achour M, Lamuela-Raventós RM, Estruch R, Landberg R,
- 779 Kulling SE, Wishart D, Rodriguez-Mateos A, et al. Revisiting the bioavailability of flavan-3-ols
- 780 in humans: A systematic review and comprehensive data analysis. Mol Aspects Med
- 781 2023;89:101146.
- 782 52. Ludwig IA, Mena P, Calani L, Borges G, Pereira-Caro G, Bresciani L, del Rio D, Lean MEJ,
- 783 Crozier A. New insights into the bioavailability of red raspberry anthocyanins and
- rellagitannins. Free Radic Biol Med 2015;89:758–69.
- 785 53. Williamson G, Kay CD, Crozier A. The Bioavailability, Transport, and Bioactivity of Dietary
- 786 Flavonoids: A Review from a Historical Perspective. Compr Rev Food Sci Food Saf
- 787 2018;17:1054–112.
- 788 54. Wang L, Halquist MS, Sweet DH. Simultaneous determination of gallic acid and gentisic acid in
- 789 organic anion transporter expressing cells by liquid chromatography-tandem mass
- spectrometry. Journal of Chromatography B 2013;937:91–6.
- 791 55. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang Y-S, Hosoya K, Terasaki T. Rat Organic Anion
- 792 Transporter 3 (rOAT3) is Responsible for Brain-to-Blood Efflux of Homovanillic Acid at the
- Abluminal Membrane of Brain Capillary Endothelial Cells. Journal of Cerebral Blood Flow &
- 794 Metabolism 2003;23:432–40.
- 795 56. Poniedziałek B, Rzymski P, Pięt M, Gąsecka M, Stroińska A, Niedzielski P, Mleczek M, Rzymski
  796 P, Wilczak M. Relation between polyphenols, malondialdehyde, antioxidant capacity, lactate

797 dehydrogenase and toxic elements in human colostrum milk. Chemosphere 2018;191:548–

798 54.

- 57. Li W, Hosseinian FS, Tsopmo A, Friel JK, Beta T. Evaluation of antioxidant capacity and aroma
  guality of breast milk. Nutrition 2009;25:105–14.
- 801 58. Silberstein T, Hamou B, Cervil S, Barak T, Burg A, Saphier O. Colostrum of Preeclamptic
- 802 Women Has a High Level of Polyphenols and Better Resistance to Oxidative Stress in
- 803 Comparison to That of Healthy Women. Oxid Med Cell Longev 2019;2019:1–5.
- Vitale DC, Piazza C, Melilli B, Drago F, Salomone S. Isoflavones: estrogenic activity, biological
  effect and bioavailability. Eur J Drug Metab Pharmacokinet 2013;38:15–25.
- 806 60. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Isoflavone content of infant formulas and
- the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr 1998;68:1453S-1461S.
- 808 61. Rosa F, Mercer KE, Lin H, Sims CR, Pack LM, Goode G, Badger T, Andres A, Yeruva L. Early
- 809 Infant Formula Feeding Impacts Urinary Metabolite Profile at 3 Months of Age. Nutrients
  810 2020;12:3552.
- 811 62. Vandenplas Y, Castrellon PG, Rivas R, Gutiérrez CJ, Garcia LD, Jimenez JE, Anzo A, Hegar B,
- Alarcon P. Safety of soya-based infant formulas in children. British Journal of Nutrition
  2014;111:1340–60.
- Andres A, Cleves MA, Bellando JB, Pivik RT, Casey PH, Badger TM. Developmental Status of 1Year-Old Infants Fed Breast Milk, Cow's Milk Formula, or Soy Formula. Pediatrics
  2012;129:1134–40.
- 817 64. Cordle CT;, Winship TR;, Schaller JP;, Thomas DJ\*;, Buck RH;, Ostrom KM;, Jacobs JR;, Blatter
- 818 MM;, Cho S, Gooch WMI, et al. Immune Status of Infants Fed Soy-Based Formulas With or
- 819 Without Added Nucleotides for 1 Year: Part 2: Immune Cell Populations. J Pediatr
- 820 Gastroenterol Nutr 2002;34:145–53.

821	65.	Ostrom KM, Cordle CT, Schaller JP, Winship TR, Thomas DJ, Jacobs JR, Blatter MM, Cho S,
822		Gooch WM, Granoff DM, et al. Immune Status of Infants Fed Soy-Based Formulas With or
823		Without Added Nucleotides for 1 Year: Part 1: Vaccine Responses, and Morbidity. J Pediatr
824		Gastroenterol Nutr 2002;34:137–44.
825	66.	Ward E, Yang N, Muhlhausler BS, Leghi GE, Netting MJ, Elmes MJ, Langley-Evans SC. Acute
826		changes to breast milk composition following consumption of high-fat and high-sugar meals.
827		Matern Child Nutr 2021;17.
828	67.	Williamson G. Reporting of plasma antioxidant activities in human intervention studies in the
829		British Journal of Nutrition. British Journal of Nutrition 2019;122:721–2.
830	68.	Harnly J. Antioxidant methods. Journal of Food Composition and Analysis 2017;64:145–6.
831	69.	Ghanim H, Sia CL, Korzeniewski K, Lohano T, Abuaysheh S, Marumganti A, Chaudhuri A,
832		Dandona P. A Resveratrol and Polyphenol Preparation Suppresses Oxidative and
833		Inflammatory Stress Response to a High-Fat, High-Carbohydrate Meal. J Clin Endocrinol
834		Metab 2011;96:1409–14.
835		70. Min J, Wang Z, Liang C, Li W, Shao J, Zhu K, Zhou L, Cheng J, Luo S, Yu L, et al.
836		Detection of Phytoestrogen Metabolites in Breastfed Infants' Urine and the
837		Corresponding Breast Milk by Liquid Chromatography–Tandem Mass Spectrometry. J
838		Agric Food Chem 2020;68:3485-94.
839		

840

841 Table 1 – Characteristics of studies detecting and quantifying (poly)phenols in human breast milk samples of mothers undergoing dietary interventions.

Diet/ Intervention	Duration of intervention	Sample type	N	Dietary recommendations and intake	Samples collected during intervention	Time of collection	Sample Treatment	Method of detection	(Poly)phenol detected	Reference
Dark chocolate	Single dose	Μ	2	No ingestion of other coca-based products	0, 2, 4, 6, 8, 10 and 12h	Whole BM content, upon pre- defined timepoint for collection.	Acidification with $PO_4H_3$ followed by SPE	UPLC- QQQ	Flavan-3-ols (epicatechin derivatives) Phenyl-γ-valerolactones	(40)
125g of red raspberry	1 week	Μ	1	-	0h and 2h on day 1 and day 7	-	SPE	UPLC- QTOF UPLC- QQQ	Anthocyanins Flavan-3-ols Flavonols Urolithins Phenyl- γ-valerolactones Phenolic acids	(44)
30g of peeled	3 days	М	11	Avoid ellagitannin containing foods during the week	0, 24, 48, and 72h	Entire BM content at the pre- defined timepoint:	ACN/formic acid (99:1)	UPLC- QTOF	Urolithins	(46)
Walliot			27	intervention	72h	Morning collection.	onicotion			
500 mL soybean milk	Single dose	Μ	6	Isoflavones restriction	0.5, 3, 6, 9, 12 and 24h	Unknown amount of BM at the pre-defined timepoint for collection	Glucuronidase and sulfatase ACN	UPLC- Qtrap	lsoflavones (genistein/daidzein)	(35)
250 mL of red grapefruit juice	Single dose	Μ	14	No supplement usage Avoid fruits rich in naringenin	0, 1, 2, 3, 4, 5, 6, 12, 18, 24 and 36h	Entire BM content at the pre- defined timepoint for collection	Hexane Pepsin in HCI NaOH and glucuronidase and sulfatase Ethyl acetate extraction	HPLC-UV HPLC- Q	Flavanones (naringenin)	(41)

5, 10 or 20g of roasted	Day 0 day 1 and day 3	М	1	No alcohol Maintained regular diet	а	Unknown amount of BM at the	Glucuronidase and sulfatase	HPLC-UV HPLC-ECD	lsoflavones (genistein/daidzein)	(39)	
soybeans	respectively			diet		timepoint for collection	extraction	HPLC-UV GC-MS	lsoflavones (genistein/daidzein)	(37)	
5, 10, and 20 g roasted soybeans	day 1 and day 3 respectively	M, IF	1	No alcohol Maintained regular diet	a	Unknown amount of BM at the pre-defined timepoint for collection	Glucuronidase and sulfatase Ethyl acetate extraction	HPLC-UV	lsoflavones (genistein/daidzein)	(38)	
250mL soy drink		М	18		Day before	5 min after					
300mL black tea	Daily (in the morning) for 6 days	М	18	<ul> <li>No consumption of flavonoid-rich beverages and foods</li> </ul>	intervention. Day 3, 6 of intervention. Day after	n. breastfeedin f g starts n. (collected in the evening	Glucuronidase and sulfatase SPE	HPLC-ECD	lsoflavones (genistein/daidzein)	(36)	
300mL water		Μ	8		Intervention	at ron a.m)					
Onion soup	Single dose	Μ	11	5-day low quercetin diet	0, 3, 6, 12, 18, 24, 36, and 48 h	Unknown amount of BM at the pre-defined timepoint of collection	Hexane Glucuronidase and sulfatase Ethyl acetate extraction	HPLC- PDA-MS	Flavonols (Quercetin/ isorhamnetin)	(42)	
227g of pomegranate juice	Daily for 2 weeks	М	2	2 weeks washout period of low (poly)phenol diet	Collection at day 0 and day 14 at 6 and 24 h post intake.	10mL of BM at the pre- defined timepoint of collection	ACN SPE	LC- MS/MS	Urolithins (Uro A glucuronide/ Dimethyl ellagic acid glucuronide)	(47)	
227g of pomegranate juice	Daily for 2 weeks	Μ	12	2 weeks washout period of low (poly)phenol diet	Collection at day 0 and day 14 at 6 and 24 h after intake.	Unknown amount of BM at the pre-defined timepoint of collection	ACN SPE	LC- MS/MS	Urolithins (Uro A glucuronide/ Dimethyl ellagic acid glucuronide)	(43)	

843 BM- Breast Milk, C- Colostrum, T- Transitional Milk, M- Mature Milk, IF- infant formula, ACN-acetonitrile, SPE- solid phase extraction, LC- Liquid

844 chromatography, HPLC- High performance liquid chromatography, UPLC/UHPLC- Ultra performance liquid chromatography, PDA- photodiode array

 $845 \qquad detector, \ ECD- \ electrochemical \ detector, \ UV- \ ultraviolet, \ GC- \ Gas \ chromatography, \ PO_4H_3 - phosphoric \ acid$ 

<sup>a</sup> The three articles mentioned share the same experimental design. Exact sampling timepoints are not mentioned in text yet are shown in graph.

847 Notwithstanding, exact timepoint of collection could not be extracted from the graphs.

859 Table 2- Characteristics of studies detecting and quantifying (poly)phenols in human breast milk samples of free-living mothers.

Criteria for participa tion	Dietary recall or FFQ	Sample type	No volunteers	Samples collected during interventio n	Time of collection	Sample Treatment	Method of detection	(poly)phenol detected	Reference
Adherenc e to Mediterra nean Diet. (based on FFQ)	FFQ	C, T, M, IF	C: 7 <sup>a</sup> T: 7 <sup>a</sup> M: 7 <sup>a</sup> IF: 7	C: up to 5 <sup>th</sup> day T:6 <sup>th</sup> - 15 <sup>th</sup> day M> 15 <sup>th</sup> day	Beginning of each feeding	NaOH hydrolysis Hexane lipid precipitation Ethyl acetate extraction	UPLC- MS/MS	Phenolic acids Flavan-3-ols Flavonols	(9)
-	FFQ and 24h recall questionnaire in the day of sampling	С, Т, М	C: 3 T: 11 M: 10	C: 1 <sup>st</sup> - 5 <sup>th</sup> T:6 <sup>th</sup> - 15 <sup>th</sup> M> 15 <sup>th</sup> day	30-50mL of BM in the morning or through the day	Acidification with $PO_4H_3$ SPE	UPLC- MS/MS	Flavan-3-ols Phenolic acids	(40)
-	-	C, T, M, IF (non- differentia ted)	6	-	Pool of different timepoints	NaOH hydrolysis Hexane lipid precipitation Ethyl acetate extraction	HPLC-UV	Phenolic acids	(57)
-	Volunteers divided in three groups according to FFQ: Low, medium, and higher (poly)phenol intake	М	30 volunteers for high and medium intake and 29 for low intake	Between 2 and 24 months	Entire BM content. All participant sample at the same time of the day	Hexane Acidified and treated with glucuronidase Ethyl acetate extraction	UHPLC- MS/MS	Flavan-3-ols Flavonols Flavanones Isoflavones	(2)
Free living	-	Т, М	T: 17 M: 17	1, 4 13 weeks after infant birth	Morning between 10h and 13h	Hexane Pepsin in HCI NaOH and glucuronidase and sulfatase Ethyl acetate extraction	HPLC- MS/MS	Flavan-3-ols Flavanones Flavonols	(14)
Free living	-	С	13	-	-	Hexane (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> and ascorbic acid Glucuronidase and sulfatase	LC-ESI- MS/MS	Flavanones Isoflavones Phenolic	(48)

						treatment Ethyl acetate and acetonitrile extraction		acids	
Free living	FFQ and 24h dietary recall	-	50	-	>30 mL of BM in the morning after fasting	Ethyl acetate extraction Glucuronidase and sulfatase treatment Ethyl acetate extraction	LC- MS/MS	lsoflavones	(70)

860 BM- Breast Milk, C- Colostrum, T- Transitional Milk, M- Mature Milk, IF- infant formula, ACN-acetonitrile, SPE- solid phase extraction, LC- Liquid

861 chromatography, HPLC- High performance liquid chromatography, UPLC/UHPLC- Ultra performance liquid chromatography, PO<sub>4</sub>H<sub>3</sub> – phosphoric acid.

<sup>a</sup> Eighteen volunteers were included in each group, yet (poly)phenol quantifications were only performed to 7 of the 18 volunteers per group.

## 864 Table 3- Dietary Flavonoids and metabolites detected in human breast milk, and their

## 865 concentrations.

Flavonoids	Milk	Concentration	Reference
	туре	(range) in	
Anthocyanins			
Cvanidin-3-sophoroside	Μ	RQ	(44)
Cvanidin-3-2G-glucosylrutinoside	M	RQ	(44)
Cvanidin-3-glucoside	M	R.Q.	(44)
Pelargonidin-3-sophoroside	M	R.Q.	(44)
Cvanidin-3-rutinoside	M	R.Q.	(44)
Cvanidin-3-glucuronide	M	R.Q.	(44)
Methylcvanidin-3-sophoroside	M	R.Q.	(44)
Peonidin-3-glucoside	M	RQ	(44)
Flavonols			
Quercetin	Μ	150 °	(2) <sup>†</sup>
	Т	48.1 (40.0-77.6)	$(14)^{\dagger}$
	M	59.8 (33.1-108.6) <sup>e</sup>	()
	M	68 <sup>b</sup>	(42) <sup>†</sup>
	C	105.22 (100.59 -	$(48)^{\dagger}$
	-	109.52) <sup>d</sup>	()
Isoquercetin	С	0.11 (0.06-0.15)	(9)
	Т	0.19 (0.08-0.21)	(-)
	М	0.16 (0.06-0.25)	
Kaempferol	М	30 °	(2) <sup>f</sup>
•	Т	15.7 (7.8-34)	(14) †
	Μ	34.8 (17.7-71.4) <sup>e</sup>	
Kaempferol-3-glucoside	С	2.36 (0-7.08)	(9)
	Т	3.02 (0.01-5.24)	
	Μ	-	
Flavan-3-ols			
Catechin	С	0.04 (0.02-0.05)	(9)
	Т	0.02 (0.01-0.03)	
	М	0.29 (0.08-0.42)	
Catechin-glucuronide	М	R.Q.	(44)
	M	<u>5.4</u> °	(2)
Epicatechin	М	33 °	(2)
	Т	90.5 (68.3-120.5)	(14)
	M	249.2(63.7-828.5)°	
Epicatechin-4-glucuronide	С, Т	38	(40)
Epicatechin-2-sulfate	Т, М	<u>26</u>	(40)
Methylepicatechin-3-sulfate	С, Т, М	26	(40)
Epicatechin-gallate	T	189.5 (55.7-609)	(14) '
	M	236.6 (62.2-646) *	
Epigallocatechin-gallate	Т	1119 (426-2365)	(14)
·	M	667 (215-1684) °	
Isoflavones		00.0	(a) 1
Daidzein	M	68 °	(2)
	M	104 ~	(35)
	Μ	60 <sup>3, 4</sup>	(38)
	М	9.3 <sup>b</sup>	(36)
	M	55 <sup>b, d</sup>	(37) <sup>†</sup>
	C	14.20 (0.83-79.46) <sup>d</sup>	$(48)^{t}$
	-	37 (20-54)	(70) <sup>†</sup>

Genistein	М	99 <sup>b</sup>	(35) <sup>†</sup>
	М	65 <sup>b, d</sup>	(38) <sup>†</sup>
	N 4	4 <b>c</b> b	(00)
	M	4.5 ~	(36)
	Μ	70 <sup>b, d</sup>	(37) <sup>r</sup>
	С	13.43 (0.93- 44.77) d	(48) <sup>†</sup>
	-	117 (105-130)	(70) <sup>f</sup>
Flavanone			
Naringenin	М	474 <sup>c</sup>	(2) <sup>†</sup>
	Т	252 (83-543)	(14) <sup>†</sup>
	Μ	210 (98-722) <sup>e</sup>	
	М	908 <sup>b</sup>	(41) <sup>†</sup>
	С	6.69 (1.41-22.30) <sup>d</sup>	(48) <sup>†</sup>
Hesperitin	Т	459 (107-1272)	(14) <sup>†</sup>
	Μ	393 (80-1603) <sup>e</sup>	
	С	4.11 (0.79-16.21) <sup>d</sup>	(48) <sup>†</sup>
Flavonoid metabolite			
Equol	Μ	102 <sup>°</sup>	(2) <sup>t</sup>
	-	8.000 (0.001-0.028)	(70) <sup>†</sup>

866 C- Colostrum, T- transitional milk, M- Mature Milk, R.Q.- Relative quantification

867

<sup>a</sup> The concentrations listed are the highest concentrations reported in each study or a range when

869 more than one concentration is presented . Studies reporting only relative quantification are

870 referred as R.Q (relative quantification).

<sup>b</sup> Studies reporting a Cmax values from a kinetic study.

872 <sup>c</sup> Highest reported concentration between the three experimental groups in the study (low, medium

and high (poly)phenol consumers).

<sup>d</sup> Approximate values extrapolated from the graph.

<sup>e</sup> Highest reported concentration between week 4 and 13 postpartum.

<sup>f</sup> This study reported the use of deconjugation enzymes that may impact the absolute value

877 reported.

### 878 Table 4 – Ellagic acid metabolites detected and quantified in human breast milk, and their

# 879 concentrations.

				000
Ellagic acid metabolites	Milk Type	Quantification Cmax (range) in nmol/L	Refere	ence
Dimethyl Ellagic Acid-glucuronide	Μ	1.12 <sup>°</sup>	(47)	883
Urolithin A	Μ	4.7 (4-5) <sup>a</sup>	(46)	884
		3.3 (1.4-7.8) <sup>b</sup>		885
Urolithin A-glucuronide	Μ	27.6 (9-78) <sup>a</sup>	(46)	886
		31 (10-90) <sup>¤</sup>		007
	Μ	36.28 <sup>°</sup>	(43)	007
Urolithin A-sulfate	Μ	7.9 (7-9) <sup>a</sup>	(46)	888
		17.2 (7-40) <sup>b</sup>		889
Isourolithin A	М	2.7 (2-5) <sup>b</sup>	(46)	890
Isourolithin A-glucuronide	Μ	14.8 (6-23) <sup>b</sup>	(46)	891
Urolithin B	М	4.3 <sup>b</sup>	(46)	892
Urolithin B-glucuronide	Μ	19.8 (5-52) <sup>b</sup>	(46)	893
Urolithin B-sulfate	Μ	D.Q	(46)	894

895

896 M- Mature Milk, D.Q- Detected not quantified

897 <sup>a</sup> Detected in Metabotype A

898 <sup>b</sup> Detected in Metabotype B

<sup>c</sup> Maximal reported Cmax between the two participants and day 1, 7 and 14 after beginning of the

900 intervention.

## Table 5- Low molecular weight phenolics detected in human breast milk, and their concentrations.

Phenolic Metabolite	Milk Type	<b>Concentration</b> (range) in nmol/L <sup>a</sup>	Reference
Benzenes			
1,2,3-trihydroxybenzene	С	0.75 (0.34-1.73)	(9)
(pyrogallol)	Т	0.95 (0.28-2.13)	
	М	1.66 (1.41-3.91)	
Benzoic acids			
3,4,5-trihydroxybenzoic acid	C	582 (3/5-/21)	(9)
(gailic acid)	I NA	661 (434 - 616)	
	M	<u>61 <sup>C</sup></u>	$(2)^{\mathrm{f}}$
	M	RO	(2)
	C	186 92 (178 70-194 57) <sup>d</sup>	(44) (48) <sup>f</sup>
2.3-dihydroxybenzoic acid	M	R 0	(40)
2 5-dihydroxybenzoic acid	C	5 61 (4-8)	$(9)^{\dagger}$
	Ť	7.41 (3-15)	(0)
	М	6.43 (0.29-11)	
2,6-dihydroxybenzoic acid		R.Q.	(44)
4-hydroxy-3-methoxybenzoic acid	С	5.96 (6-7)	(9) <sup>f</sup>
(vanillic acid)	Т	7.05 (6-8)	
	М	6.56 (4-10)	
	М	R.Q.	(44)
3-methoxybenzoic acid-4-sulfate (vanillic acid-sulfate)	М	R.Q.	(44)
3-methoxybenzoic acid-4-glucuronide (vanillic acid-glucuronide)	М	R.Q.	(44)
4-methoxy-3-hydroxybenzoic acid	Μ	R.Q.	(44)
4-methoxy-benzoic acid-3-sulfate	М	R.Q.	(44)
3.4-dihydroxybenzoic acid	С	15,16 (5-31)	(9) <sup>†</sup>
(protocatechuic acid)	Ť	22.55 (9-27)	(0)
,	Μ	13.16 (3-20)	
	М	770 °	(2) <sup>†</sup>
	М	R.Q.	(44)
3,4-dihydroxybenzoic acid-sulfate <sup>b</sup> (protocatechuic acid-sulfate)	Μ	R.Q.	(44)
2,4,6-trihydroxybenzoic acid	С	2.71 (1-6)	(9)
, , ,	Т	2.68 (1-4)	(-)
	Μ	3.08 (0.25-6)	
4-hydroxybenzoic acid	С	0.54 (0.24-0.90)	(9)
	Т	0.67 (0.44-0.94)	
	М	0.72 (0.26-1.9)	
	M	R.Q.	(44)
	С, I, М	(4445-4598) <sup>u</sup>	(57)
benzoic acid-4-glucuronide	М	R.Q.	(44)
benzoic acid-4-sulfate	M	R.Q.	(44)
3-hydroxybenzoic acid	C T	7.66 (3-14) 9.94 (6-12)	(9)
	М	6.85 (3-8)	
benzoic acid-3-glucuronide	Μ	R.Q.	(44)
methyl 4-hydroxybenzoate	Μ	R.Q.	(44)
methyl 3,4-dihydroxybenzoate	М	R.Q.	(44)

Benzaldehydes			
3,4-dihydroxybenzaldehyde	С	9.63 (3-17)	(9)
(protocatechualdehyde)	Т	12.56 (7-16)	
	М	7.46 (3-10)	
	Μ	R.Q.	(44)
4-hydroxybenzaldehyde (p-hydroxybenzaldehyde)	М	R.Q.	(44)
	С	1.09 (1-6)	(9)
	Т	3.54 (1-5)	
h a secoldada da stranova stata	M	1.62 (0.41-3)	
Denzaldenyde-4-glucuronide (4-bydroxybenzaldebyde-glucuronide)	IVI	R.Q.	(44)
4-hydroxy-3-methoxybenzaldehyde	C	5 84 (3-9)	(9)
(vanillin)	т	7.83 (7-10)	(3)
( , )	M	5.56 (2-10)	
2-hydroxy-3-methoxybenzaldehyde	С	1.61 (1.41-1.62)	(9)
(o-vanillin)	Т	6.06 (6-7)	
	М	12.22 (0.30-32)	
2,4,6-trihydroxybenzaldehyde	М	R.Q.	(44)
(phloroglucinaldehyde)			
Cinnamic Acids			
cinnamic acid	М	R.Q.	(44)
(coumaric acid)			
4'-hydroxy-3'-methoxycinnamic acid	С	0.62 (0.06-1.23)	(9)
(ferulic acid)	Т	0.71 (0.12-1.53)	
	М	0.34 (0.14-0.57)	
	М	129 <sup>°</sup>	(2)'
	М	R.Q.	(44)
	С, Т,	(7339-7673) <sup>d</sup>	(57)
	M		(
3'-methoxycinnamic acid-4'-glucuronide (ferulic acid-glucuronide)	M	R.Q.	(44)
3',4'-dihydroxycinnamic acid	C	14.15 (4-17)	(9)
(caffeic acid)	I N/I	17.28 (4-30)	
		12.32 (1-24)	$(2)^{\dagger}$
	IVI	100	(2)
	С	301.95 (129.32- 654.97) <sup>d</sup>	(48) <sup>†</sup>
(caffeic acid-sulfate)	M	R.Q.	(44)
4'-methoxycinnamic acid	C	0.24 (0.02-0.67)	(9)
	I M	0.30 (0.14-0.48)	
3' 4'-dimethoxycinnamic acid	C	0.14 (0.13-0.28)	(9)
(dimethylcinnamic acid)	Ť	0.56 (0.15-0.25)	(0)
	M	0.18 (0.13-0.24)	
4'-hydroxycinnamic acid	С	0.44 (0.24-0.59)	(9)
(p-coumaric acid)	Т	1.20 (0.27-2.31)	
	Μ	0.29 (0.15-0.49)	
	С, Т, М	(8474-8797) <sup>a</sup>	(57)
cinnamic acid-4'-sulfate (p-coumaric acid-sulfate)	Μ	R.Q.	(44)
3-(phenyl)propanoic acids			

3-(3'-methoxyphenyl)propanoic acid-4'- glucuronide (dihydroferulic acid-glucuronide)	М	R.Q.	(44)
3'-methoxycinnamic acid-4'-sulfate (dihydroferulic acid-sulfate)	Μ	R.Q.	(44)
3-(3',4'-dihydroxyphenyl)propanoic acid-sulfate <sup>b</sup> (dihydrocaffeic acid-sulfate)	М	R.Q.	(44)
3-(3'-hydroxyphenyl)propanoic acid	М	R.Q.	(44)
3-(phenyl)propanoic acid-3'-sulfate (3-(3-hydroxyphenyl)propanoic acid-sulfate) Phenylacetic acids	М	R.Q.	(44)
2'-hydroxyphenylacetic acid	М	R.Q.	(44)
3'-hydroxyphenylacetic acid	М	R.Q.	(44)
4'-hydroxyphenylacetic acid	Μ	R.Q.	(44)
4'-hydroxyphenylacetic acid ( <i>p</i> -hydroxyphenylacetic acid)	C T M	0.27 (0.05-0.53) 0.41 (0.35-0.52) 0.40 (0.07-0.93)	(9)
3',4'-dihydroxyphenylacetic acid (dopac)	Μ	277 °	(2) <sup>t</sup>
	Μ	R.Q.	(44)
4'-hydroxy-3'-methoxyphenylacetic acid (homovanillic acid)	Μ	R.Q.	(44)
3'-hydroxy-4'-methoxyphenylacetic acid (Isohomovanillic acid)	Μ	R.Q.	(44)
5-(phenyl)-γ-valerolactone			
5-(3',4 -dihydroxyphenyl)-γ-valerolactone- glucuronide (isomer 1) <sup>b</sup>	М	26	(40)
5-(3',4'-dihydroxyphenyl)-γ-valerolactone- glucuronide (isomer 2) <sup>b</sup>	C T M	37 (22-39) (19-39)	(40)
5-(3',4'-dihydroxyphenyl)-γ-valerolactone-sulfate	C T M	(165-781) (24-1909) (20-435)	(40)
5-(3'-methoxyphenyl)-γ-valerolactone-4'-	M	24	(40)
5-(3'-methoxy-4'-hydroxyphenyl)-γ- valerolactone-sulfate <sup>e</sup>	T M	(14-26) (17-20)	(40)
5-(3'-methoxy-4'-hydroxyphenyl)-γ- valerolactone-sulfate <sup>e</sup>	C T M	20 20 17 (16 9-17 2)	(40)
5-(3',4',5'-trihydroxyphenyl)-y-valerolactone	M	R.Q.	(44)
5-(4'-hydroxyphenyl)-γ-valerolactone-3'- glucuronide	Μ	R.Q.	(44)
$5-(3',4'-dihydroxyphenyl)-\gamma-valerolactone-sulfate$	Μ	R.Q.	(44)
Hippuric Acids			
hippuric Acid	Μ	R.Q.	(44)
Chlorogenic acids			

chlorogenic acid	С	9.43 (0.57-26.82)	(9)
-	Т	17.72 (2.39-40.02)	
	Μ	1.03 (0.01-2.61)	

<sup>903</sup> C- Colostrum, T- transitional milk, M- Mature Milk, R.Q.- Relative quantification

<sup>a</sup> The concentrations listed are the highest concentrations reported in each study or a range when more than one concentration is presented. Studies reporting only relative quantification are referred as R.Q (relative guantification).<sup>b</sup> The concentration reflects the sum of two possible isomers; <sup>c</sup> Highest reported concentration between the three experimental groups in the study (low, medium, and high (poly)phenol consumers); <sup>d</sup> Converted from µg/L to nmol/L; <sup>e</sup>The original manuscript states two sulfate isomers for "5-(3<sup>Ω</sup>-methoxy-4<sup>Ω</sup>-hydroxyphenyl)-γ-valerolactone-sulfate". However, this molecule only has one hydroxyl group available for sulfation. For this reason, it is possible that the isomers mentioned in the original manuscript are 5-(32-methoxyphenyl)-y-valerolactone-42-sulfate and 5-(42-methoxyphenyl)-y-valerolactone-32-sulfate.